Background: Autoimmune diseases such as lupus and rheumatoid arthritis have a very significant cardiovascular risk. There are a very few studies that evaluate the cardiovascular risk during primary sjogren syndrome (pSS).

Objectives: To evaluate the modifiable cardiovascular risk in primary sjogren syndrome (pSS).

Methods: We conducted a retrospective study of all patients fulfilling the 2016 ACR/EULAR classification criteria for pSS. We collected the patient characteristics, age, sex, disease activity …….. current treatments and also modifiable cardiovascular risk factors s (body-mass index, systolic blood pressure, non–high-density lipoprotein cholesterol, current smoking, and diabetes).

Results: 57 patients were included with a median age of 61.2 [22-87] years, among which 53 (93%) were women.The duration of disease progression of 6.7 years [2-25] and ESSDAI 3.3[0-12].

Among 52 (92.8%) with a positive labial salivary gland biopsy (LSGB), 19 (40%) Ssa postive, 10(18%) Ssb positive, 37 (66%) FR positive, and mean gammaglobulin 14.5 g/l[4.6-46.9].

About modifiable cardiovascular risk factors; BMI 27[4.6-46.9], with 49% overweight(28/57) and 23%(13/57) obese.High blood pressure in 3%(n=13), tobacco 9%(n=5), 7% diabetes 2 (n=4) and dyslipdémia 46%(n=19).

Amoung 36/57 patients with a lipid profile: total cholesterol 4.64 mmol [3.09- 6.65], with 31%(n=11) having hyperCT >5.20 mmol/l, and 30% associated with non-HDL cholesterol level mor than 2.58 mmol/l.

Regarding tratements: all patient with hight blood pressure have a treatement, 7%(n=4) oral antidiabetics drug, and 12%(n=7) have a Cholesterol-lowering therapy.

Our results confirm the frequency of modifiable cardiovascular risk in primary sjogren syndrome (pSS).

Furthermore in ours series, we noted an increase of hypercholesterolaemia but not hight blood pressure[1]. All our patients with hypertension and diabetes mellitus have a treatements, but 36%(4/11) of hypercholesterolaemia not treated, 18% insufficiently treated but 30% of patients had an LDL level more than therapeutic objective for patient swith inflammatorry disease(>1g/l).

Conclusion: pSS is associated with an increased risk of cardiovascular risk, and requires multidisciplinary care(cardiologist, rheumatologistic and en endocrinologist).

REFERENCES: [1] Cardiovascular disease risk burden in primary sjogren’s syndrome: results of a population-based multicentre cohort study.E Bartoloni et al.The journal of internal médicine 2015.

Acknowledgements: NIL.

Disclosure of Interests: None declared.